40
White JH, Fernandez I, Mader S and Yang X-J (2004) Vitam Horm. 68:123-43. Corepressor recruitment by agonist-bound nuclear receptors.
39
Bourdeau V, Deschênes J, Metivier R, Nagai Y, Nguyen D, Hudson T, White J, Gannon F, and Mader S. (2004).Mol Endocrinol. 18(6):1411-27 Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol.
38
Mercier I, Mader S, Calderone A (2003). Cardiovascular Res 59:883-92. Tamoxifen and ICI182,780 negatively influence cardiac cell growth via an estrogen receptor-independent mechanism.
37
Davison K, Cote S, Mader S, Miller WH. (2003) Leukemia 17(5):931-40. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.
36
Rousseau C, Pettersson F, Couture MC, Paquin A, Galipeau J, Mader S and Miller WH Jr. (2003) J. Steroid. Biochem. Mol. Biol., 86:1-14. The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells.
35
Brodeur H, Gagnon I, Mader S and Bhat PV. (2003) J. Lipid. Research, 44:303-313. Cloning of monkey RALDH1 and characterization of retinoid metabolism in monkey kidney proximal tubule cells.
34
Fernandes I, Bastien Y, Wai T, Nygard K, Lin R, Cormier O, Lee HS, Eng F, Bertos NR, Pelletier N, Mader S, Han V, Yang XJ and White JH. (2003) Mol. Cell 11: 139-50. Ligand-dependent corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms.
33
Guimond J, Devost D, Brodeur H, Mader S and Bhat PV (2002) Biochem. Biophys. Acta 1579:81-91. Characterization of the rat RALDH1 promoter. A functional CCAAT and octamer motif are critical for basal promoter activity.
32
Montplaisir, V., Chow Lan N, Guimond J, Bhat PV and Mader S. (2002) J. Biol. Chem. 277: 17486-17492 Retinal oxydizing enzyme activity of recombinantly expressed rat kidney and phenobarbital-induced aldehyde dehydrogenases.
31
Barsalou A, Dayan G, Anghel SI, Carrière J, Alaoui-Jamali M, Van de Velde P, and Mader S. (2002) Mol. Cell. Endocrinol., 190: 65-73. Growth stimulatory and transcriptional activation properties of raloxifene in endometrial Ishikawa cells.
30
Mercier I, Mader S, Calderone A (2002). Cardiovascular Res. 53:728-39. Ovarian hormones induce TGF-beta(3) and fibronectin mRNAs but exhibit a disparate action on cardiac fibroblasts proliferation.
29
Sanchez R, Nguyen D, Rocha W, White JH and Mader S (2002) BioEssays, 24:244-54. Diversity in the mechanisms of gene regulation by estrogen receptors.
28
Nguyen D, Steinberg SV, Rouault E, Chagnon S, Gottlieb B, Pinsky L, Trifiro M and Mader S. (2001) Mol. Endocrinol. 15: 1790-1802. The G577R mutation in the human androgen receptor P box results in selective decreases in DNA binding and in partial androgen insensitivityA syndrome.
27
Akutsu, N, Bastien Y, Lin R, Mader S and White JH (2001) Biochem. Biophys. Res. Comm. 281: 1051-56. Amphiregulin is a vitamin D target gene in squamous cell and breast carcinoma.
26
Jaalouk D, Eliopoulos N, Couture C, Mader S and Galipeau J. (2000) Human Gene Therapy 11: 1837-49. Glucocorticoid-inducible retrovector for regulated transgene expression in genetically engineered bone marrow stromal cells.
25
Yen L, You X-L, Al Moustafa, A-E, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali, M (2000) Oncogene 19: 3460-9. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
24
Anghel S, Perly V, Barsalou A, Carrière J, Rosenauer A, Miller WH Jr and Mader S. (2000) J. Biol. Chem. 275:20867-72. Amino acid asparate 351 in the ligand binding domain of estrogen receptor a is not crucial for the antagonist activity of antiestrogens.
23
Rosenauer A, Nervi C, Davison K, Lamph WW, Mader S and Miller WH Jr (1998) Cancer Res. 58: 5110-6. Estrogen receptor expression activates the transcriptional and growth inhibitory response to retinoid without enhanced RARa expression.
22
Eng FCS, Barsalou A, Akutsu, N., Mercier I., Zechel C, Mader S and White JH (1998) J. Biol. Chem. 273: 28371-7. Different classes of coactivators recognize distinct but overlapping binding sites on the estrogen receptor ligand binding domain.
21
Bhat PV, Marcinkiewicz M, Li Y, and Mader S (1998) J. Histochem. Cytochem. 46(9):1025-32. Changing patterns of renal RALDH expression parallel nephron development in the rat.
20
Le Bihan S, Marsaud V, Mercier-Bodard C, Baulieu EE, Mader S, White JH, and Renoir JM (1998) Mol. Endocrinol. 12:986-1001. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells.
19
Barsalou A, Gao W, Anghel SI, Carrière J, and Mader S (1998) J. Biol. Chem. 273:17138-46. Estrogen response elements can mediate agonist activity of anti-estrogens in human endometrial Ishikawa cells.
18
Whalen S, Gingras AC, Amankwa L, Mader S, Branton P, Aebersold R and Sonenberg N (1996) J. Biol. Chem.; 271:11831-7. Phosphorylation of eIF-4E on Serine 209 by protein kinase C is inhibited by the translational repressors, 4E-binding proteins.
17
Haghighat A, Mader S, Pause A, and Sonenberg N (1995) EMBO J.14, 5701-9. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E.
16
Mader S, Lee H, Pause A, and Sonenberg N. (1995) Mol. Cell. Biol. 15, 4990-7. Protein-protein interactions involving the cap-binding protein (eIF-4E): role of an amino acid motif present in several 4E-binding proteins.
15
Mader S, and Sonenberg N (1995) Biochimie 1-2:40-4. Cap-binding proteins and the control of cellular growth.
14
White JH, McCuaig KA, and Mader S (1994) Bio/Technology 12:1003-7. A simple and sensitive high-throughput assay for steroid agonists and antagonists.
13
Mader S, Breuer B, and Alonso A (1994) J. Mol. Biol. 242:37-44. The promoter of the H10 histone gene contains a retinoic acid response element.
12
Mader S, Chen J-Y, Chen Z, White JH, Chambon P, and Gronemeyer H. (1993) EMBO J. 12:5029-41. The patterns of binding of RAR, RXR and TR homo- and heterodimers to direct repeats are dictated by the binding specificities of the DNA binding domains.
11
Mader S and White JH. (1993) Proc. Natl. Acad. Sci. USA 90:5603-7. A novel steroid-inducible promoter for the controlled overexpression of cloned genes in eukaryotic cells.
10
Mader S, Chambon P, and White AJH (1993) Nucleic Acids Res. 21:1125-32. Defining a minimal oestrogen receptor DNA binding domain.
9
Mader S, Leroy P, Chen J-Y, and Chambon (1993) J. Biol. Chem. 268:591-600. Multiple parameters control the selectivity of nuclear receptors for their response elements.
8
Kruyt F, van der Veer L, Mader S, van der Brink CE, Feijen A, Jonk LJC, Kruijer W, and Van der Saag P (1992) Differentiation 49:27-37. Retinoic acid resistance of the variant embryocarcinoma cell line RAC65 is caused by expression of a truncated RAR alpa=23.
7
Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, Chen J-Y, Staub A, Garnier JM, Mader S, and Chambon P (1992) Cell 1992; 68:377-95. Purification, cloning and RXR identity of the HeLa factor with which RAR or TR heterodimerizes to bind target sequences efficiently.
6
Vasios G*, Mader S*, Gold JD, Leid M, Lutz Y, Gaub M-P, Chambon P, and Gudas L (1991) EMBO J. 10:1149-58. The late retinoic acid induction of the laminin B1 gene transcription involves RAR binding to the responsive element (*equal first authors).
5
Truss M, Chalepakis G, Slater EP, Mader S, and Beato M (1991) Mol. Cell Biol. 10:3247-58. Functional interaction of hybrid response elements with wild-type and mutant steroid hormone receptors.
4
Nicholson RC, Mader S, Nagpal S, Leid M, Rochette Egly C, and Chambon P (1991) EMBO J. 9:4443-4454. The negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 element.
3
Guerrier D, Boussin L, Mader S, Josso N, Kahn A, and Picard J-Y (1990) J. Reprod. Fertil. 88:695-706. Expression of the gene for anti-mullerian hormone.
2
Mader S, Kumar V, de Verneuil H, and Chambon P (1989) Nature 338:271-4. Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen- from a glucocorticoid-responsive element.
1
Tora L, Gaub M-P, Mader S, Dierich A, Bellard M. and Chambon P (1988) EMBO J. 7:3771-8. Cell specific activity of a GGTCA half-palindromic oestrogen-responsive element.